Home Neurologic and Psychiatric Genetic Markers Frontotemporal Dementia Genetic Test: MAPT, GRN, C9orf72, and Results

Frontotemporal Dementia Genetic Test: MAPT, GRN, C9orf72, and Results

By
Vita Library
-
3
Learn how MAPT, GRN, and C9orf72 testing is used in frontotemporal dementia, what positive or uncertain results mean, and how relatives are affected.

Frontotemporal dementia genetic testing looks for inherited causes of progressive changes in behavior, personality, language, executive function, or movement. The three most common genes in monogenic frontotemporal dementia are C9orf72, GRN, and MAPT, but they do not cause disease through the same mechanism or produce one predictable clinical pattern. C9orf72 testing requires a dedicated repeat-expansion assay, whereas GRN and MAPT are usually evaluated by sequencing and deletion or duplication analysis. A pathogenic result can establish the molecular cause, clarify whether amyotrophic lateral sclerosis or parkinsonism belongs to the same family disorder, and allow adult relatives to consider targeted predictive testing. It cannot reliably forecast the exact age of onset, first symptom, rate of decline, or duration of illness. Because results may affect relatives who did not request testing and may influence planning, insurance, employment, and reproductive decisions, pretest and posttest genetic counseling are central to responsible use. The test is most informative when interpreted alongside a specialist clinical assessment, neuropsychological testing, imaging, biomarkers, and a detailed three-generation family history.

  • Genetic testing should be considered in confirmed frontotemporal dementia even when the documented family history appears negative.
  • A complete strategy must include a specific C9orf72 repeat-expansion test; standard sequencing alone may miss it.
  • GRN pathogenic variants usually reduce progranulin and are associated with TDP-43 pathology, while MAPT variants lead to tau-related disease.
  • Most established genetic forms are autosomal dominant, giving each child of a carrier a 50% chance of inheriting the variant.
  • A variant of uncertain significance is not a diagnosis and should not be used for predictive testing in healthy relatives.

Table of Contents

Why Genetic Testing Is Considered in FTD

Frontotemporal dementia, or FTD, is a clinical spectrum rather than one uniform disease. It results from degeneration of frontal and temporal brain networks and may first appear as loss of judgment, empathy, motivation, social restraint, language ability, or motor function. Memory can be relatively preserved early, although memory impairment may also occur. The condition is an important cause of dementia beginning before the typical age for Alzheimer disease, but onset can occur across a wide adult age range.

A substantial minority of people with FTD have a single-gene cause. The likelihood is highest when multiple relatives have FTD, motor neuron disease, unexplained early-onset dementia, primary progressive aphasia, atypical parkinsonism, or major behavioral change. However, an apparently negative family history does not rule out inherited disease. Earlier generations may have been labeled with Alzheimer disease, Parkinson disease, psychiatric illness, alcoholism, institutionalization, or an unspecified dementia. Relatives may have died before reaching the usual age of onset, and smaller families can conceal a dominant pattern. In C9orf72 and GRN families, age-related or incomplete penetrance can also make a parent appear unaffected.

Current specialist practice is moving toward offering genetic counseling and testing to everyone with a well-supported FTD-spectrum diagnosis, not only those with an obvious multigenerational history. The reasons include meaningful diagnostic yield in apparently sporadic cases, access to gene-specific research, and the importance of establishing a familial variant while the affected person is available for testing.

Testing the person with symptoms first is usually the most informative approach. A pathogenic variant found in an affected relative creates a clear target for other family members. Starting with an unaffected relative before the family cause is known can produce an unhelpful negative result because it may be unclear whether the correct gene or variant was tested.

The genetic test does not replace clinical diagnosis. Behavioral or language symptoms can arise from Alzheimer disease, Lewy body disease, vascular injury, autoimmune or infectious disease, tumors, medication effects, sleep disorders, substance use, mood disorders, psychosis, or other neurologic conditions. The clinician must determine that the presentation is progressive and compatible with neurodegeneration before treating a genetic finding as explanatory.

Clinical Patterns That Shape the Test

The phenotype helps the laboratory and clinician choose an appropriate test, but it rarely identifies the gene with certainty. Considerable overlap exists among C9orf72, GRN, MAPT, and rarer FTD genes.

Behavioral-variant FTD often begins with disinhibition, apathy, reduced empathy, compulsive behavior, altered food preferences, impaired judgment, or loss of insight. These changes can be mistaken for depression, bipolar disorder, obsessive-compulsive disorder, a personality disorder, or a primary psychotic illness. A progressive loss of function, neurologic signs, characteristic imaging, and collateral history from someone who knows the person well help distinguish neurodegeneration from a longstanding psychiatric pattern.

Primary progressive aphasia presents with a gradual decline in language. Nonfluent or agrammatic speech may occur in FTD-spectrum disease, while semantic-variant disease causes loss of word and object meaning. A logopenic pattern is more often associated with Alzheimer pathology, although the clinical boundaries are not absolute. GRN variants can produce language-predominant disease, sometimes with striking asymmetry on imaging.

Motor findings are particularly useful clues. FTD with amyotrophic lateral sclerosis, upper or lower motor neuron signs, bulbar dysfunction, or a family history of ALS raises concern for a C9orf72 expansion. C9orf72 carriers can develop FTD, ALS, both, or occasionally a different neuropsychiatric or movement-dominant presentation. The gene cannot predict which end of this spectrum a carrier will develop.

Atypical parkinsonism may point toward MAPT or GRN, but neither association is exclusive. MAPT families can show behavioral FTD, parkinsonism, progressive supranuclear palsy-like features, or corticobasal syndrome. GRN disease can also produce corticobasal syndrome, asymmetric movement abnormalities, language impairment, or memory symptoms. The same pathogenic variant may lead to different syndromes among relatives.

A three-generation pedigree should therefore document more than the word “dementia.” Useful details include age at first symptom, language or personality change, ALS, weakness, swallowing difficulty, parkinsonism, falls, psychiatric hospitalization, suicide, and the age and cause of death of apparently unaffected relatives. An uncertain family history should broaden testing rather than justify excluding the major genes.

What C9orf72, GRN, and MAPT Results Represent

C9orf72 repeat expansion

The principal disease-causing C9orf72 alteration is a large expansion of a six-letter DNA sequence, GGGGCC, in a noncoding region of the gene. The expansion can reduce normal C9orf72 function and generate toxic RNA and abnormal dipeptide-repeat proteins. Brain pathology is commonly associated with TDP-43.

This expansion is a major genetic link between FTD and ALS. A carrier may develop behavioral FTD, language impairment, ALS, combined FTD-ALS, or other features. Age at onset varies widely, and penetrance is age dependent. Some older carriers remain asymptomatic, while others develop disease much earlier.

Repeat size reported from blood is not a dependable personal prognostic marker. Large expansions are technically difficult to measure, may vary among tissues, and can show mosaicism. The presence of a pathogenic expansion is clinically important; an exact repeat count usually cannot tell a family when symptoms will begin or whether the presentation will be ALS rather than FTD.

GRN pathogenic variants

GRN encodes progranulin, a protein involved in lysosomal function, inflammation, and neuronal health. Most pathogenic GRN variants cause loss of function in one gene copy, lowering progranulin levels through haploinsufficiency. The associated brain pathology is typically TDP-43 rather than tau.

GRN-related disease is highly variable. Behavioral-variant FTD, nonfluent primary progressive aphasia, corticobasal syndrome, parkinsonism, and prominent memory symptoms can all occur. Neuroimaging may show marked asymmetry, but that pattern is not diagnostic on its own.

Low blood progranulin can support the interpretation of a suspected loss-of-function GRN variant and may help identify people who need genetic evaluation. It is not a standalone diagnostic test for FTD, and levels can be affected by assay and biological factors. The DNA result, variant classification, clinical phenotype, and sometimes family segregation remain central.

Rarely, pathogenic changes in both GRN copies cause a childhood-onset lysosomal storage disorder rather than typical adult FTD. This distinction matters for reproductive counseling when both partners carry pathogenic GRN variants.

MAPT pathogenic variants

MAPT encodes the microtubule-associated protein tau. Pathogenic variants can alter tau structure, function, or the balance of tau isoforms, leading to abnormal tau accumulation. MAPT-related FTD is therefore strongly associated with tau pathology.

The phenotype may include early behavioral change, executive dysfunction, language impairment, parkinsonism, rigidity, gaze abnormalities, or corticobasal features. Penetrance for many established MAPT variants is high, but onset and progression still vary substantially. A parent’s age at onset may offer family context, not a precise prediction for a child.

Not every rare MAPT change is pathogenic. Some missense or intronic variants require detailed evidence about functional effect, population frequency, prior affected families, and segregation. A VUS in MAPT should not be converted into a diagnosis simply because the clinical picture resembles FTD.

Building a Complete Testing Strategy

An effective FTD test must cover different classes of genetic variation. The most common error is ordering standard sequencing without confirming that C9orf72 repeat-expansion analysis is included. Short-read sequencing and many exome tests are not designed to size this expansion reliably.

A typical diagnostic strategy includes:

  1. A dedicated C9orf72 hexanucleotide repeat-expansion assay.
  2. Sequencing of GRN, MAPT, and other validated FTD or FTD-ALS genes.
  3. Deletion and duplication analysis, because sequencing may miss exon-level or whole-gene copy-number changes.
  4. Additional testing selected for the phenotype, family history, ancestry, and prior results.

Many laboratories offer an FTD, dementia, or FTD-ALS panel. The gene list should be reviewed rather than accepted based on the panel name. Rarer causes may include variants in genes associated with motor neuron disease, multisystem proteinopathy, leukodystrophy, prion disease, or other neurodegenerative syndromes. Including genes without a well-established relationship to the phenotype can increase uncertain results, so breadth should be balanced with interpretability.

The C9orf72 report should state the assay used and how the laboratory defines normal, intermediate, and pathogenic ranges. Repeat-primed PCR can detect an expansion pattern, while other methods may be used to estimate size or resolve ambiguous results. Laboratories differ in whether they provide an exact estimate, a lower bound, or a qualitative “expanded” result. Borderline findings may require confirmation with an independent method or testing of relatives.

GRN and MAPT analysis should include adequate coverage of coding exons and relevant splice regions. Copy-number analysis is important for GRN because pathogenic deletions can occur. Genome sequencing may eventually combine more of these variant classes, but users must still verify whether the laboratory has validated C9orf72 repeat detection and reporting.

Before testing, the ordering team should discuss consent, possible secondary findings if exome or genome sequencing is used, sample storage, data reanalysis, and how results will be shared. Because cognitive or behavioral impairment can affect decision-making capacity, the person should be involved as fully as possible, with a legally appropriate representative when necessary. Testing should not be performed solely for relatives while ignoring the affected person’s rights and preferences.

Interpreting Positive, Uncertain, and Negative Results

Pathogenic or likely pathogenic result

A pathogenic C9orf72 expansion or a pathogenic or likely pathogenic variant in GRN or MAPT can establish the molecular cause of an FTD-spectrum illness when the phenotype is compatible. It also identifies the familial alteration that can be tested in adult relatives.

The classification “likely pathogenic” reflects strong evidence, not absolute certainty, and is generally used clinically much like “pathogenic.” The report should specify the gene, variant, inheritance pattern, laboratory evidence, and limitations. For a sequence variant, checking whether it is expected to cause loss of function, alter splicing, or disrupt a known functional domain helps explain why it was classified.

A positive result does not prove that every symptom is caused by the gene. A carrier can also have depression, vascular disease, medication effects, sleep apnea, seizures, or another neurologic condition that requires separate evaluation. Nor does the result reveal the exact microscopic pathology in every case, although gene-pathology associations can be strong.

Variant of uncertain significance

A VUS is a change for which available evidence is insufficient or conflicting. It should not confirm FTD, determine treatment, or be used to test healthy relatives for future disease. Testing affected and unaffected family members may sometimes help the laboratory evaluate segregation, but relatives should not receive a “positive” or “negative” predictive interpretation based on a VUS.

Variant classification can change. Families should retain the report and confirm whether the laboratory offers periodic reanalysis or amended reports. A clinician may also submit updated clinical details or family data that improve interpretation.

Negative result

A negative panel means no reportable pathogenic alteration was found by the methods used. It does not mean the condition is non-genetic. The causal gene may be absent from the panel, the variant may be technically difficult to detect, or scientific evidence may not yet be sufficient to classify it.

The most important quality check is whether C9orf72 expansion testing was actually performed. A negative exome result without a dedicated repeat assay leaves a major cause incompletely assessed. The clinician should also verify copy-number coverage and whether the test could identify structural, intronic, mitochondrial, or repeat variants relevant to the presentation.

Unexpected or dual findings

Broad testing may identify a pathogenic variant associated with a different dementia, movement disorder, or motor neuron syndrome. It can also uncover two findings. The team must determine which, if either, matches the phenotype. A genetic diagnosis should be based on evidence rather than the assumption that any rare result explains the illness.

What a Genetic Diagnosis Changes

The immediate value of a molecular diagnosis is explanatory. It can end a prolonged search, connect apparently different diagnoses within a family, and clarify whether FTD and ALS belong to one inherited spectrum. It also prevents repeated low-yield testing and allows relatives to receive focused counseling.

Gene identity may influence clinical vigilance. C9orf72 warrants awareness of motor neuron signs such as progressive weakness, muscle wasting, fasciculations, spasticity, and bulbar symptoms. GRN disease can be markedly asymmetric and may produce corticobasal or language-predominant features. MAPT disease may include parkinsonism and other tau-associated syndromes. These associations guide attention but should not become rigid predictions.

Management remains symptom based and multidisciplinary. Neurology, neuropsychiatry, speech-language therapy, occupational and physical therapy, social work, palliative care, and caregiver support may all be needed. Behavioral symptoms, swallowing, communication, mobility, driving, medication safety, finances, and advance care planning should be addressed early, while the person can participate.

A confirmed variant may establish eligibility for observational studies or gene-targeted clinical trials. Research programs are developing approaches intended to restore progranulin, modify tau biology, or reduce toxic C9orf72 products. Trial availability, inclusion criteria, risks, and evidence change over time. A genetic result creates a possible pathway to research participation; it does not guarantee access or therapeutic benefit.

The result can also support neuropathologic planning. Families may consider brain donation or autopsy programs, particularly when clinical and molecular findings are unusual. Such programs can confirm pathology and contribute to research, but participation is voluntary and should be discussed before a crisis.

Predictive Testing for Relatives

Most pathogenic C9orf72 expansions and pathogenic GRN or MAPT variants are inherited in an autosomal dominant manner. Each child of a carrier has a 50% chance of inheriting the familial alteration. The same applies to full siblings when one parent is a carrier. A person who does not inherit the familial pathogenic variant is generally not at increased genetic risk from that specific cause and cannot pass it to children.

Inheritance of the variant is not the same as a precise prediction of disease. Penetrance differs by gene and variant and is often age dependent. Age at onset, first syndrome, severity, and duration may differ greatly within one family. C9orf72 can lead to ALS, FTD, or both; GRN can present with behavioral, language, movement, or memory features; and MAPT phenotypes also vary.

Predictive testing should occur only after the family’s pathogenic variant has been confirmed in an affected person whenever possible. Testing a healthy relative with a broad panel is less informative and creates a greater risk of uncertain findings.

A structured predictive-testing process usually includes pretest counseling, neurologic and psychological review, discussion of motivations, assessment of support, and a plan for receiving the result. Topics may include emotional impact, family communication, reproductive choices, privacy, insurance and employment protections, research options, and the possibility that no proven prevention strategy exists. Laws differ by country and may not protect life, disability, or long-term-care insurance in the same way as health insurance.

Adults at risk may choose testing, postpone it, or decline it. All are valid choices. Some people want certainty for family planning or life decisions; others prefer not to know while asymptomatic. Pressure from relatives, clinicians, or researchers should not replace voluntary informed consent.

Predictive testing is generally not offered to children for adult-onset FTD when no childhood medical intervention is available. Preserving the child’s future autonomy is the usual priority. Testing may be reconsidered if symptoms arise or if a specific familial condition has recognized childhood manifestations.

Reproductive options can include prenatal diagnosis or preimplantation genetic testing once the familial pathogenic variant is known. These decisions are personal and require specialist counseling about technical limits, timing, costs, and local law.

When Testing Does Not Explain the Condition

An unresolved result should trigger a methodical review rather than the conclusion that nothing more can be learned. The clinician should confirm the clinical diagnosis, re-examine the pedigree, and compare the phenotype with the test’s actual technical coverage.

If C9orf72 expansion analysis was omitted, it should be performed. If only the three major genes were tested, a broader FTD-ALS or dementia panel may be reasonable. Exome or genome sequencing can identify rare sequence and structural variants, but the laboratory’s repeat-expansion capability must be checked separately. Mitochondrial testing, prion-gene analysis, leukodystrophy testing, or other specialized assays may be appropriate for particular imaging or neurologic findings.

The diagnostic evaluation should also address non-FTD causes. Alzheimer biomarkers may be useful when language or memory symptoms could reflect Alzheimer disease. Autoimmune, infectious, metabolic, vascular, toxic, medication-related, sleep, and psychiatric explanations require targeted assessment. A person can have a strong family history and still have a different, potentially treatable condition.

Reanalysis is valuable because gene-disease evidence and variant classifications evolve. Laboratories may reinterpret stored sequence data after new discoveries, and genome or long-read technologies may later detect variants missed by earlier methods. DNA banking preserves material for future testing when the affected person’s health is declining.

When no molecular diagnosis emerges, relatives should not be given falsely precise risk estimates. Their risk may still be higher than the population risk because of family history, but targeted predictive testing is impossible without a known familial variant. Genetics professionals can explain empirical risk, research opportunities, and what changes in symptoms should prompt evaluation.

A well-conducted negative evaluation is still useful. It documents which major causes were assessed, protects relatives from acting on a VUS, and creates a clear starting point for future reanalysis. The central question is not simply whether a test is “positive,” but whether the complete clinical and laboratory evidence supports a reliable explanation for the family’s disease.

References

Disclaimer

This article is for general education and does not replace a dementia specialist’s assessment, genetic counseling, or individualized medical advice. Genetic findings can have implications for biologic relatives and should be interpreted by professionals familiar with FTD, ALS, repeat-expansion testing, and variant classification. Urgent evaluation is needed for rapidly progressive symptoms, new swallowing or breathing difficulty, severe weakness, unsafe behavior, or an immediate risk of harm.

RELATED ARTICLESMORE FROM AUTHOR